Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.59 |
| ▸ | FPR2 | P25090 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CPA1 | P15085 | 4/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL27550557 | 1.00 | MME (0.59) | MMEFPR2L3MBTL1NPSR1ACE | |
| SCHEMBL627437 | 1.00 | MME (0.59) | MMEFPR2L3MBTL1NPSR1ACE | |
| SCHEMBL754129 | 1.00 | MME (0.59) | MMEFPR2L3MBTL1NPSR1ACE | |
| Benzene SCHEMBL27550555 | 1.00 | MME (0.59) | MMEFPR2L3MBTL1NPSR1ACE | |
| Benzene SCHEMBL27569477 | 1.00 | MME (0.59) | MMEFPR2L3MBTL1NPSR1ACE | |
| SCHEMBL2720887 | 0.95 | MME (0.61) | MMEFPR2L3MBTL1ACECPA1 | |
| SCHEMBL24534147 | 0.94 | MME (0.61) | MMEFPR2L3MBTL1ACEALDH1A1 | |
| SCHEMBL24534148 | 0.94 | MME (0.61) | MMEFPR2L3MBTL1ACEALDH1A1 | |
| SCHEMBL19888359 | 0.92 | MME (0.65) | MMEACECPA1ACE2 | |
| SCHEMBL2720880 | 0.92 | MME (0.65) | MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| US-20190135810-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES | PTC THERAPEUTICS INC (US) | 2019-05-09 | — | — | US | claimed |
| US-20120136154-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES | PTC THERAPEUTICS, INC. | 2012-05-31 | — | — | US | claimed |
| JP-8099947-A | — | — | None | — | — | JP | disclosed |
| US-12187715-B2 | Small molecule activators of Tie-2 | EyePoint Pharmaceuticals, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | EyePoint Pharmaceuticals, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240190857-A1 | METHODS FOR MANUFACTURE OF SMALL MOLECULE ACTIVATORS OF TIE-2 | EyePoint, Inc. | 2024-06-13 | — | — | US | disclosed |
| WO-2024043313-A1 | REVERSIBLE THERMOCHROMIC COMPOSITION, MICROENCAPSULATED PIGMENT USING SAID REVERSIBLE THERMOCHROMIC COMPOSITION, WRITING TOOL, AND TOY | 三菱ケミカル株式会社 | 2024-02-29 | — | — | WO | disclosed |
| CN-116940355-A | Method for manufacturing small molecule activators of TIE-2 | 视点制药公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230265087-A1 | SMALL MOLECULE ACTIVATORS OF TIE-2 | EyePoint, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-11613534-B2 | Small molecule activators of Tie-2 | EyePoint Pharmaceuticals, Inc. (US) | 2023-03-28 | — | — | US | disclosed |
| JP-H0899947-A | PRODUCTION OF HALOGENATED ALPHA-AMINOKETONE AND ALPHA-AMINOALCOHOL | F HOFFMANN LA ROCHE AG | 1996-04-16 | — | — | JP | disclosed |
| WO-1995004056-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1995-02-09 | — | — | WO | disclosed |
| EP-0252216-B1 | MICROBIOLOGICALLY PRODUCED ALPHA-ACETYLAMINO CINNAMIC ACID ACYLASE, METHOD OF ITS PRODUCTION AND ITS USE | Degussa Aktiengesellschaft (DE) | 1992-01-29 | — | — | EP | disclosed |
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4877734-A | CULTURING TWO BREVIBACTERIUM SPECIES; ENZYMATIC CONVERSIONS | Degussa Aktiengesellschaft and Gesellschaft fur biotechnologische Forschung-mit beschrankter Haftung GBF (DE) | 1989-10-31 | — | — | US | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0252216-A2 | Microbiologically produced alpha-acetylamino cinnamic acid acylase, method of its production and its use | Degussa Aktiengesellschaft (DE) | 1988-01-13 | — | — | EP | disclosed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | disclosed |
| US-4533745-A | Amino ketones and their preparation | MERCK & CO., INC. (US) | 1985-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190857-A1 | METHODS FOR MANUFACTURE OF SMALL MOLECULE ACTIVATORS OF TIE-2 | TIE1, TEK, KDR | MME 1515/4885FPR2 1928/4885L3MBTL1 4392/4885 |
| US-11613534-B2 | Small molecule activators of Tie-2 | TIE1, TEK, KDR | MME 1488/4885FPR2 1422/4885L3MBTL1 3323/4885 |
| US-20230265087-A1 | SMALL MOLECULE ACTIVATORS OF TIE-2 | TIE1, TEK, KDR | MME 1488/4885FPR2 1422/4885L3MBTL1 3323/4885 |
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | TIE1, TEK, KDR | MME 1654/4885FPR2 1086/4885L3MBTL1 4715/4885 |
| US-20120136154-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES | TPH1, TPH2, HTR1B | MME 3874/4885FPR2 3990/4885L3MBTL1 3771/4885 |
| US-12187715-B2 | Small molecule activators of Tie-2 | TIE1, TEK, KDR | MME 1488/4885FPR2 1422/4885L3MBTL1 3323/4885 |
| US-20190135810-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES | TPH1, TPH2, HTR1B | MME 3865/4885FPR2 3980/4885L3MBTL1 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.